We are live on ! Find out more
BIOTW

Biotech Acquisition Company Warrant
BIOTW

Delisted

BIOTW was delisted on the 2nd of February, 2023.

Back to rankings

51 hedge funds and large institutions have $3.8M invested in Biotech Acquisition Company Warrant in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 5 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more funds holding

Funds holding: 48 → 51 (+3)

13% less capital invested

Capital invested by funds: $4.35M → $3.8M (-$551K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 5

Holders
51
Holders Change
+3
Holders Change %
+6.25%
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
5
Closed
–
Calls
$5.72M
Puts
–
Net Calls
+$5.72M
Net Calls Change
+$4K

Top Buyers

Rank Fund Capital Flow
1
PC
Periscope Capital
Ontario, Canada
+$5.81K
2
PCM
Prelude Capital Management
New York
+$1.09K

Top Sellers

Rank Fund Capital Flow
1
BFM
Boothbay Fund Management
New York
-$1.46K
2
MC
Meteora Capital
Florida
-$298
3
UBS Group
UBS Group
Switzerland
-$84
4
Citadel Advisors
Citadel Advisors
Florida
-$82
5
HIM
HGC Investment Management
Ontario, Canada
-$70

BIOTW Hedge Fund Activity: Q3 2022 in Review

51 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q3 2022, worth a combined $3.8M — down 13% from $4.35M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new BIOTW positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 5 trimmed.

The largest buyer was Periscope Capital, opening a new position worth an estimated $5.81K. The largest seller was Boothbay Fund Management, cutting an estimated $1.46K.

  • 51 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q3 2022, up from 48 in Q2 2022.
  • Funds reported $3.8M of Biotech Acquisition Company Warrant stock for Q3 2022, down 13% quarter-over-quarter.
  • 3 funds opened new Biotech Acquisition Company Warrant positions in Q3 2022 and 0 closed out, a net change of +3 holders.
  • The largest Biotech Acquisition Company Warrant buyer in Q3 2022 was Periscope Capital, an estimated $5.81K added.
  • The largest Biotech Acquisition Company Warrant seller in Q3 2022 was Boothbay Fund Management, an estimated $1.46K sold.

Based on aggregated 13F filings for Q3 2022.